Lynch syndrome (LS) is the most common hereditary cancer syndrome. While identifying LS is essential, detecting cancers early in those already diagnosed is just as critical. Now, a major new initiative is tackling that challenge head-on, with leadership from one of Lynsight’s own.
The PREDI-LYNCH project, a groundbreaking European research initiative, has received €13.6 million in funding from the EU’s Horizon Europe program to revolutionize how cancer is detected in patients already diagnosed with LS. The initiative brings together a powerhouse consortium of scientists, clinicians, and institutions across Europe, all working toward a single goal: to develop precision strategies for identifying LS-associated cancers earlier and more accurately than ever before.
Among the key contributors is Dr. Toni Seppälä, a leading expert in colorectal and hereditary cancer, active member of multiple international expert groups, and a trusted member of the Lynsight Clinical Advisory Board. His involvement reflects both the scientific strength of the project and its strong ties to real-world clinical impact.
At Lynsight, we are proud to spotlight this milestone in LS research. As a company focused on identifying individuals with Lynch syndrome through accessible, reliable diagnostic tools, we know that enabling targeted cancer surveillance and early intervention for those already diagnosed will save lives.
A United Effort with Global Reach
Led by Oslo University Hospital, PREDI-LYNCH includes a diverse network of academic and clinical leaders, including Tampere University’s Faculty of Medicine and Health Technology. Together, the consortium spans numerous European countries and centers of excellence in hereditary cancer research and care.
Their joint mission is clear: to create and validate next-generation tools that can detect cancer in LS patients at the earliest, most treatable stages, particularly in populations that are currently underserved or overlooked by standard surveillance.
While genetic testing helps identify individuals with LS, there remains an urgent need for improved methods to monitor these individuals over time. PREDI-LYNCH addresses this critical gap by developing innovative strategies that help ensure cancers don’t go undetected until it’s too late.
Lynch syndrome increases the lifetime risk of colorectal, endometrial, ovarian, and several other cancers, often developing earlier than in the general population. Despite clear diagnostic criteria and the availability of genetic testing, it’s estimated that up to 53-65% of individuals with LS remain undiagnosed. This underdiagnosis is one of the greatest barriers to effective prevention.
A Model for the Future of Cancer Prevention
PREDI-LYNCH is more than a research initiative. This project represents a shift in mindset from reactive to preventive oncology. Its emphasis on early prevention and intervention aligns with the broader evolution in healthcare toward personalized medicine and risk-based screening. By detecting cancer early, clinicians can recommend risk-reducing measures and preventive treatment plans. Families can make informed decisions. And ultimately, lives can be saved.
At Lynsight, this approach aligns closely with our mission. We know that delays in diagnosis or gaps in long-term monitoring can deeply impact individuals and their families. That’s why we’re focused on delivering reliable solutions across the entire LS journey—from identifying those with Lynch syndrome through our validated DiagMMR assay, to supporting complementary efforts like PREDI-LYNCH that aim to improve ongoing cancer surveillance. Together, these tools represent a more proactive, personalized model of care.
The Importance of Collaboration
One of the most remarkable aspects of PREDI-LYNCH is its spirit of international collaboration. No single institution can solve hereditary cancer detection on its own. It takes partnerships across borders, disciplines, and sectors to bring research into clinical practice. Dr. Seppälä exemplifies this collaborative approach—bridging research and clinical expertise across institutions and countries to help shape a more proactive, data-driven model for early detection.
This project exemplifies what’s possible when public health institutions, academic researchers, clinicians, and industry stakeholders unite around a shared goal. And its success could lay the foundation for improved strategies not only for Lynch syndrome, but for other hereditary cancer syndromes as well.
Looking Ahead
As the PREDI-LYNCH project progresses, we look forward to seeing how its innovations translate into real-world impact, both in clinical settings and in the lives of patients and families affected by LS.
At Lynsight, we’ll continue to support research, education, and clinical partnerships that drive forward the early detection of hereditary cancers. Because when it comes to Lynch syndrome, early detection isn’t just a clinical edge—it’s the key to saving lives.
We’re honored to be part of a global community working to bring clarity, care, and control to individuals navigating their risk for hereditary cancer. And we’re excited to see how initiatives like PREDI-LYNCH help shape a future where no one is left undiagnosed or unaware.
Stay tuned for updates as this important project unfolds—and as always, reach out to Lynsight to learn more about DiagMMR, other LS research initiatives, and our commitment to early LS detection.